Clinical Trials

Upcoming or Currently Enrolling Clinical Trials In Gastroenterology


NORTRIPTYLINE FOR IDIOPATHIC GASTROPARES: A MULTICENTER RANDOMIZED, DOUBLE-MASKED, PLACEBO-CONTROLLED TRIAL (NORIG) IRB00006003

The Section on Gastroenterology is recruiting people with gastroparesis for a research study.The purpose of this study is to determine whether nortriptyline or placebo improves symptoms of gastroparesis of unknown cause. Participants will be involved in the research study for 18 weeks and will be compensated for their time.

For more information about the study, please contact Judy at 336-713-7301 or Samantha at 336-713-2602


Furture Enrollment once IRB approved: Pilot Study of the Safety, Feasibility, and Potential Efficacy of Continuous Glucose Monitoring and Insulin Pump Therapy in Diabetic Gastroparesis (GLUMIT-DG)  IRB00010957

This is a study designed to assess the safety of a Continuous Glucose Monitoring System (CGMS) when used to direct insulin pump therapy for 24 weeks in subjects with type 1 diabetes and type 2 diabetes and gastroparesis. This study will be enrolling 20 subjects with type 1 and 20 subjects with type 2 diabetes and gastroparesis at seven NIH clinical centers. Subjects will be 18-70 years old. The expected duration of the study for an individual subject will be 24 weeks. Participants will receive compensation. For more information call Judy at 336-713-7301.

ACCORDIS:
IRB approval # BG 05-254

A Double Blinded, Randomized Parallel Arm, Dose Ranging Study of IMURAN in Subjects with Active Crohn’s Disease Requiring Treatment with Prednisone: A Crohn’s Disease Optimal Range Dose of Imuran Study.
We are currently recruiting subjects who have been diagnosed with Crohn’s Disease for at least 3 months and require treatment with oral prednisone or budesonide (ENTOCORT). The length of participation in the study is approximately 9 months.

For more information please contact: Angie Boaz LPN CCRC (336) 713-7319


Open Label, Pilot Study of the Use of Conjugated Linoleic Acid in Subjects with Crohn’s Disease.
IRB approval # BG

This study is currently not open for enrollment

We will be looking for subjects between the ages of 18-50 years of age that have been diagnosed with Crohn’s disease by clinical criteria. Patients will be enrolled in the study for approximately 14 weeks. Subjects will consume the CLA supplement once daily for 12 weeks.

Compensation for time and travel may be available.

For more information please contact Angie Boaz LPN CCRC (336) 713-7319


A Pilot Study of the Effects of Dietary Soy Supplementation of Crohn’s Disease
IRB approval # BG 05-399

Currently we are looking for subjects 18 years of age and older with a diagnosis of Crohn’s disease. You must be willing to consume a soy supplement twice a day for 12 weeks. You can not have intolerance to soy or milk products. Subjects will also complete a daily diary and questionnaires at each clinic visit.

For more information please contact Angie Boaz LPN CCRC (336) 713-7319


Evaluation of Tropical 10% Metronidazole Ointment for the Treatment of Active Perianal Crohn’s Disease
IRB approval # BG 05-567

Currently we are looking for patients that have been diagnosed with Crohn’s disease with anorectal involvement. You must have had perianal symptoms for at least 3 months. Subjects will participate in the study for approximately 8 weeks.

For more information please contact Angie Boaz LPN CCRC (336) 713-7319 


(NIH) Gastroparesis Registry

Human Protocol:
This will be enrolling pending IRB approval

We will be enrolling subjects with gastroparesis. To be eligible for this study, you must be at least 18 years old and must have delayed gastric emptying and/or nausea combined with other symptoms of gastroparesis (vomiting, early satiety, and abdominal pain). Your participation could last up to four years or longer.

For more information please call Judy Hooker at 336-713-7301

Last Updated: 12-05-2014
USNWR 2013-2014Magnet Hospital RecognitionConsumer Choice2014 Best DoctorsJoint Commission Report

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.